Nabi Biopharma (NABI) Sells Aloprim
More News related to NABI
- Nabi Biopharmaceuticals (NABI) Tops Q3 EPS by 2c
- Nabi Biopharmaceuticals Announces Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Nabi Biopharmaceuticals Completes Sale of PentaStaph(TM) to GlaxoSmithKline PLC
- Nabi Biopharmaceuticals Announces Withdrawal of Biotest's Indemnification Claim
More News related to Mergers and Acquisitions
- HP (HPQ) Acquires 3Com (COMS) for $7.90 Per Share, or $2.7 Billion
- HP (HPQ) buys 3Coms (COMS) for $7.90/Share Cash
- HP (HPQ) said to buy 3Com (COMS) for $2.7B
- Motorola (MOT) is going to seek buyers for its home and networks division, which is worth roughly $4.5 billion - WSJ
- Logitech (LOGI) Acquires LifeSize Comm for $405M
Nabi Biopharmaceuticals (Nasdaq: NABI) executed a definitive agreement to sell its Aloprim for Injection product to Bioniche Teoranta. Bioniche Teoranta is based in Ireland and is part of Bioniche Pharma Group. The aggregate sale proceeds for Aloprim is $3.7 million -- Nabi will receive $1.3 million at closing, $1.4 million at the end of 2007 and $1.0 million at the end of 2008.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
